Patient selection
Candidacy for prostate artery embolization starts with the diagnosis, anatomy, health history, and your treatment priorities.
Editorially updated July 20, 2026. This educational page was prepared by SoCal Interventional using the cited primary and authoritative sources. It does not replace an individualized medical evaluation.
Quick answer: A candidate for prostate artery embolization (PAE) is generally a man with bothersome urinary symptoms attributed to benign prostatic hyperplasia (BPH) who has completed an appropriate evaluation and wants to consider a minimally invasive, image-guided treatment. Prostate size alone does not determine candidacy. Symptoms, bladder function, prostate cancer assessment, arterial anatomy, kidney function, infection status, prior treatments, medications, and personal goals all matter.
Request a PAE evaluation in Van Nuys or Irvine, California, or call (310) 929-0026.
PAE may be discussed when BPH symptoms interfere with sleep, daily activity, travel, work, or quality of life and conservative measures have not provided enough relief or are not well tolerated.
| Question | Why it matters |
|---|---|
| Are symptoms attributable to BPH? | Urinary symptoms can also arise from bladder dysfunction, infection, urethral narrowing, neurologic disease, medications, or cancer. |
| How bothersome are the symptoms? | A validated symptom score and discussion of quality of life help define the treatment goal. |
| What is the prostate size and anatomy? | Imaging and urologic evaluation help compare PAE with medications and other procedures. |
| Is prostate cancer evaluation current? | PAE treats BPH; it is not a prostate cancer treatment and does not provide tissue for pathology. |
| Is there active infection? | Urinary infection generally requires evaluation and treatment before an elective procedure. |
| Are kidney function and contrast risks acceptable? | PAE commonly uses iodinated contrast and fluoroscopic imaging. |
| Is the arterial route technically feasible? | Severe atherosclerosis, tortuous vessels, or unusual anatomy can affect difficulty and risk. |
| What outcomes matter most? | Speed of relief, catheter goals, sexual function, anesthesia, recovery, and retreatment tolerance influence the choice. |
PAE is performed through a small arterial puncture, typically at the wrist or groin. It does not require an instrument to remove prostate tissue through the urethra. Many procedures are completed in an outpatient setting, although the plan varies by patient and facility.
A large prostate does not automatically exclude PAE. The Society of Interventional Radiology’s multisociety statement identifies very large prostates among the settings in which PAE may be considered. Size still must be interpreted alongside anatomy, bladder function, cancer evaluation, symptom severity, and available alternatives.
PAE may appeal to patients who want to reduce the likelihood of ejaculatory dysfunction associated with some transurethral procedures. Published evidence generally reports fewer ejaculatory problems after PAE than after TURP, but preservation cannot be guaranteed.
Some patients with significant medical conditions may be evaluated for PAE because it often avoids general anesthesia and surgical tissue removal. Medical risk is individualized; serious heart, lung, kidney, bleeding, or vascular disease can also affect PAE safety.
PAE may be considered for some men with BPH-related retention or long-term catheter use. It does not guarantee catheter independence. Duration of retention, bladder muscle function, obstruction, prostate anatomy, infection, and other causes must be assessed.
PAE may be considered when bleeding is attributed to the prostate and other causes have been evaluated. Urinary bleeding always requires appropriate medical assessment.
The following findings may delay treatment, require another approach, or require additional specialist input. Some are relative rather than absolute limitations.
PAE is not an emergency treatment for sudden inability to urinate, severe infection, heavy bleeding, or another acute condition. Seek urgent care when instructed.
The workup is individualized and may involve both an interventional radiologist and a urologist. Possible components include:
Not every patient requires every test. The purpose is to confirm the likely cause of symptoms, assess safety, understand anatomy, and compare reasonable alternatives.
PAE can be considered across a range of prostate sizes, but no single number establishes eligibility. A 100-gram, 150-gram, or 200-gram prostate may create different technical and clinical considerations, yet symptoms and bladder function do not always correlate directly with size. Smaller prostates may also cause significant obstruction in selected patients.
Patients with persistent or recurrent symptoms after UroLift, Rezūm, GreenLight, TURP, medication, or another intervention may be evaluated for PAE. The previous procedure, current anatomy, scarring, arterial supply, residual obstruction, bladder function, and reason for persistent symptoms must be reviewed. PAE is not automatically appropriate simply because another treatment did not work.
Reasonable alternatives can include observation, behavior changes, medication, UroLift, Rezūm, Aquablation, laser procedures such as HoLEP or GreenLight, TURP, simple prostatectomy, or another plan. Availability and suitability depend on the individual case.
A balanced discussion should cover the expected speed and degree of symptom relief, anesthesia, catheter use, sexual and urinary effects, recovery, pathology needs, retreatment, clinical evidence, physician experience, and insurance coverage.
There is no universal size threshold that determines candidacy by itself. Imaging, arterial anatomy, symptoms, bladder function, cancer assessment, prior treatment, and clinical goals are considered together.
PAE may be evaluated when medication does not provide adequate relief or causes unacceptable effects. Confirming that symptoms are caused by BPH remains essential.
Some catheter-dependent patients may be considered, but successful catheter removal cannot be promised. Bladder function and the cause and duration of retention are important.
Prior BPH treatment does not automatically prevent PAE. A new evaluation is needed to determine why symptoms persist and whether embolization is technically and clinically appropriate.
Coverage varies by plan, network, medical necessity criteria, and authorization. Socal Interventional accepts most PPO plans, Medicare, self-pay, and some IPA plans, subject to individual verification.
Dr. Nathanael Sabbah evaluates PAE candidates at Socal Interventional in Van Nuys and Irvine. The goal is to determine whether BPH is the likely cause of symptoms, identify factors that affect safety or benefit, and compare PAE with appropriate urologic alternatives.
Learn how PAE works, review the PAE recovery timeline, compare PAE vs TURP, or request an appointment.
Medical disclaimer: This page provides general education and cannot determine individual candidacy. A qualified clinician must review your history, examination, testing, imaging, alternatives, and goals.
Explore more: Visit the PAE Patient Resource Center and review our Medical Editorial Policy.
